Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

The value of phase 4 clinical testing.

Vlahakes GJ.

N Engl J Med. 2006 Jan 26;354(4):413-5. No abstract available.

PMID:
16436775
2.

Aprotinin revisited.

Deanda A Jr, Spiess BD.

J Thorac Cardiovasc Surg. 2012 Nov;144(5):998-1002. doi: 10.1016/j.jtcvs.2012.06.035. Epub 2012 Jul 15. Review.

3.

Antifibrinolytics in major orthopaedic surgery.

Eubanks JD.

J Am Acad Orthop Surg. 2010 Mar;18(3):132-8. Review.

PMID:
20190103
4.

Aprotinin increases mortality as compared with tranexamic acid in cardiac surgery: a meta-analysis of randomized head-to-head trials.

Takagi H, Manabe H, Kawai N, Goto SN, Umemoto T.

Interact Cardiovasc Thorac Surg. 2009 Jul;9(1):98-101. doi: 10.1510/icvts.2008.198325. Epub 2009 Apr 20. Review.

PMID:
19380335
5.

Hemostatic drugs.

Mannucci PM.

N Engl J Med. 1998 Jul 23;339(4):245-53. Review. No abstract available.

PMID:
9673304
6.

Benefits and risks of aprotinin use during cardiac surgery.

Kristeller JL, Roslund BP, Stahl RF.

Pharmacotherapy. 2008 Jan;28(1):112-24. Review.

PMID:
18154481
7.

Current antifibrinolytic therapy for coronary artery revascularization.

Trudell J, McMurdy N.

AANA J. 2008 Apr;76(2):121-4. Review.

PMID:
18478817
8.

Mortality manifesto: a meta-analysis of aprotinin and tranexamic acid mortality.

Brown JR.

Eur J Cardiothorac Surg. 2009 Oct;36(4):781-2. doi: 10.1016/j.ejcts.2009.06.014. Epub 2009 Jul 18. Review. No abstract available.

PMID:
19616962
9.

Aprotinin: 1 year on.

Dietrich W.

Curr Opin Anaesthesiol. 2009 Feb;22(1):121-7. doi: 10.1097/ACO.0b013e32831c833f. Review.

PMID:
19295302
10.

Managing fibrinolysis without aprotinin.

Edmunds LH Jr.

Ann Thorac Surg. 2010 Jan;89(1):324-31. doi: 10.1016/j.athoracsur.2009.10.043. Review.

PMID:
20103278
11.

Safety aspects of aprotinin therapy in cardiac surgery patients.

Royston D, Chhatwani A.

Expert Opin Drug Saf. 2006 Jul;5(4):539-52. Review.

PMID:
16774492
12.

Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery?

Zufferey P, Merquiol F, Laporte S, Decousus H, Mismetti P, Auboyer C, Samama CM, Molliex S.

Anesthesiology. 2006 Nov;105(5):1034-46. Review.

PMID:
17065899
13.

[Aprotinin in the control of surgical hemorrhage].

Rocha E, Antonio Páramo J, Hermida J.

Med Clin (Barc). 1996 Mar 2;106(8):307-16. Review. Spanish. No abstract available.

PMID:
8667690
14.

Aspects of bleeding after cardiac surgery in children.

McEwan A.

Paediatr Anaesth. 2007 Dec;17(12):1126-33. Review. No abstract available.

PMID:
17986030
15.

Current status of non-transfusional haemostatic agents.

Cattaneo M, Mannucci PM.

Haematologica. 1999 Jun;84 Suppl EHA-4:120-3. Review. No abstract available.

PMID:
10907488
16.

Antifibrinolytics.

Schmarts.

Acta Anaesthesiol Belg. 2003;54(4):319-22. Review. No abstract available.

PMID:
14719353
17.

Reduction in requirements for allogeneic blood products: pharmacologic methods.

Janssens M, Hartstein G, David JL.

Ann Thorac Surg. 1996 Dec;62(6):1944-50. Review.

PMID:
8957438
18.

Efficacy and safety of aprotinin in cardiac surgery.

Levy JH.

Orthopedics. 2004 Jun;27(6 Suppl):s659-62. Review.

PMID:
15239553
19.

Antifibrinolytic use in adult cardiac surgery.

Umscheid CA, Kohl BA, Williams K.

Curr Opin Hematol. 2007 Sep;14(5):455-67. Review.

PMID:
17934352
20.

Antifibrinolytics in orthotopic liver transplantation: current status and controversies.

Xia VW, Steadman RH.

Liver Transpl. 2005 Jan;11(1):10-8. Review.

Supplemental Content

Support Center